Scivita Medical Technology has expanded its strategic collaboration with Boston Scientific through a cooperation arrangement for endoscopic devices.
Under the arrangement, the two companies will focus on the co-development of future endoscopic devices and explore global distribution opportunities.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
These activities are related to Scivita Medical’s single-use endoscope and imaging devices.
The expanded arrangement is anticipated to facilitate the availability of Scivita Medical’s products to more hospitals and patients in China and other geographies globally.
Boston Scientific Endoscopy senior vice-president and president Mike Jones said: “We are excited to further our relationship with Scivita Medical which we anticipate will help provide physicians with more device options in geographies around the world.
“We look forward to successfully building on that relationship with this new arrangement.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataScivita Medical is engaged in the research, development as well as commercialisation of medical endoscopes and related products.
Scivita Medical co-founder, general manager and chief technology officer Dr Chin said: “This strengthened relationship will help us combine our core strengths and expertise to deliver high-quality single-use endoscope solutions to doctors and patients in various regions across the globe.
“Working with a company like Boston Scientific is crucial to Scivita Medical’s globalisation strategy.”
Last year, Scivita Medical signed an agreement with Boston Scientific for its single-use percutaneous choledochoscope.
At that time, Scivita Medical said the collaboration would further broaden the market penetration of its choledochoscope.
Recently, the US Food and Drug Administration (FDA) approved the Agent drug-coated balloon, which is developed by Boston Scientific, for the treatment of coronary in-stent restenosis (ISR), obstruction or narrowing of a stented vessel.
The Agent balloon can inflate to reopen the stent and diffuse paclitaxel – a chemotherapy drug that maintains the patency of the lumen of the blood vessel.
